FDA grants fast track designation for omecamtiv mecarbil in heart failure
This selective cardiac myosin activator is being investigated in the GALACTIC-HF study and the METEORIC-HF study to determine effect of exercise capacity and CV outcomes compare to placebo.
Source:
Biospace Inc.